

NICE: BIVDA HealthTech Update

Mark Chapman
Director HealthTech

NICE National Institute for
Health and Care Excellence



Note the new name: HealthTech

- *HealthTech* is now the collective term for Diagnostics, Device & Digital, and for whatever may come next...
- You will hear us increasingly refer to all our evaluations as *HealthTech* evaluations

Why? We have undertaken extensive insights work and many know the element of each of our programmes but few understand the subtle difference, which in part discourages engagement

Why? So we can more appropriately review our offers to *HealthTech* and Medicines.

Why? Internal we are going through an organisational change that will mean all our expertise can be deployed across all the legacy programmes as demand and needs require.

- Please be note the programmes will over adapt to reflect this approach with the NICE wide ambition to have a consistent approach to processes and methods (where appropriate)*
- Please refer to the NICE Business Plan 23/24 and wider strategy available on the NICE website and Board Papers.

Business Plan 2023/24

Draft for discussion

NICE National Institute for
Health and Care Excellence



Executive summary

- The world is changing. To play our part in the future, NICE needs to continue to evolve. To better serve people and the health and care system, NICE must transform in 4 ways.
- We are focusing on what matters most, we are creating useful and usable advice, and we are part of a system that continually learns from data and implementation. To do this, we need to build a brilliant organisation.
- Our planning for 2023 and beyond reflects our core purpose, with a particular focus on using health and care resources wisely. Our business plan objectives for 23/24 are:
 - Increase the relevance of our guidance by developing a NICE-wide horizon scanning & topic selection function enabled by coordinated stakeholder engagement
 - Increase the real-world impact of our pre-evaluation support by simplifying and improving NICE's early engagement with industry
 - Make our advice easier to access by improving our digital presence
 - Increase the useability of our guidance by incorporating technology appraisals into guidelines, and evolve our supporting resource impact assessment
- Improve NHS decision making in new ways by developing a programme to provide advice on the value of classes of medtech products already in use
- Improve the timeliness of our guidance by implementing improvements to our methods and processes identified last year
- Support implementation of our guidance by improving our measurement approach, and develop an automated uptake and monitoring system for a priority topic
- Build a brilliant organisation by implementing suggestions from crowdsourcing and staff survey including: develop a continuous improvement process and capabilities and adopt NICE-wide talent management approach
- Delivering these objectives will benefit our partners and help deliver our ambition in measurable ways
- In addition, we will continue to deliver our core guidance and make good use of public funds

To better serve people and the health and care system, NICE must transform in 4 ways

NICE is a world-class organisation based on independence, transparency and rigour – that remains our foundation

Our purpose is to help practitioners and commissioners
get the best care to patients fast while ensuring value for the taxpayer

1

Focus on what matters most



*Is our advice **relevant** given pressures in health and care?*

2

Provide useful and useable advice



*Is our advice **timely** and **easy to use** for NHS and care staff?*

3

Constantly learn from data & implementation



*Does our advice reflect **learnings from real world** implementation and data?*

4

Build a brilliant organisation

*Do we have simple **processes** and enabling **technology** and **behaviours**?*



Our business plan objectives for 23/24

1

Focus on what matters most



Relevance

1. Increase the relevance of our guidance by developing a **NICE-wide horizon scanning & topic selection function** enabled by **coordinated stakeholder engagement**
2. Increase the real-world impact of our pre-evaluation support by **simplifying and improving NICE's early engagement with industry**

2

Provide useful and useable advice

Useable

3. Make our advice easier to access by **improving our digital presence**
4. Increase the useability of our guidance by **incorporating technologies into guidelines**, and **evolve our supporting resource impact assessment**
5. Improve the value of NHS purchasing in new ways by developing the programme to **provide advice on classes of HealthTech products already in use**

Timely

6. Improve the timeliness of our guidance by **implementing improvements to our methods and processes identified last year**



3

Constantly learn from data & implementation



Learning from real world data

7. Support implementation of our guidance by **improving our measurement approach**, and develop an **automated uptake and monitoring system in a priority topic**

4

Build a brilliant organisation

8. Build a brilliant organisation by implementing suggestions from crowdsourcing and staff survey including: develop a **continuous improvement process** and capabilities and adopt **NICE-wide talent management approach**



Increase the real-world impact of our pre-evaluation support by simplifying and improving NICE's early engagement with industry

NICE



Alongside our evaluations of medicines and HealthTech, NICE provides a range of early engagement functions and multiple engagement routes to support innovators from evidence generation through to market access.

We heard from our partners in industry that NICE's range of expert advice offers can be confusing and hard to navigate. We want to ensure we are working with innovators across all areas of NICE's remit, providing expert advice to enable patient access to promising technologies in priority areas.

To improve the experience of industry in their engagement with NICE we will establish a simple early engagement offer and front door to innovators and industry that brings together our current life sciences offers and addresses the needs of our users in industry. This offer will be underpinned by a customer service ethos and a common approach to providing advice to technology developers from the earliest stages of the product development cycle through to patient access and adoption.

Improve NHS decision making in new ways by developing the programme to provide advice on the value of classes of HealthTech products already in use

NICE




There is a huge volume and range of HealthTech products on the market and regularly used in the NHS. These products have wide variation in evidence base and price. It is an impossible task for clinicians, managers and commissioners to identify which products offer genuine innovation, and which do and do not offer good value.

NICE's HealthTech programme does not typically evaluate products which are already widely used across the NHS. There is also no standardised method to compare between products of the same class. This means that there is no clear value signal for clinicians, managers, and commissioners, so NHS resources are not always used as effectively as they should be.

To address this situation, we will extend NICE's HealthTech programmes to cover technologies which are already adopted and used in the NHS. NICE's advice for these product classes would help direct purchasing and clinical decisions towards the most clinically and cost effective products, helping improve patient outcomes and make the best use of public money.

Providing advice on classes of HealthTech products already in use

By the end of 23/24 we will have:



Delivering our objectives will make tangible differences for our users, and lay the foundations for the future

Focus on what matters most



Provide useful and useable advice



Constantly learn from data & implementation



Visible

More NICE guidance that addresses major population health and/or operational challenges

A new-look NICE website with easier navigation and clearer explanations of what we do

Guideline recommendations formatted in a way that makes it easier to read and easier to find what you're looking for

Workforce and capacity impacts of guidance explained in a meaningful way for local systems

Faster guidance production across all NICE programmes

Single front door for early engagement with industry

Foundational

Aligned methods between programmes to enable integrated guidance

New product and channel strategy and enabling content management systems

A reproducible approach for automated monitoring of NICE guidance uptake, to enable implementation support and allow continuous evaluation

Improved ways of working and enhanced competencies

Delivering these objectives will benefit our stakeholders

Patient: I have faster access to new treatments, even where NICE needs more data to be able make a final decision.

Clinician: I can more easily find what I'm looking for in NICE's guideline content.

Manager: NICE guidance clearly sets out the resource implications so I can help implement technologies or service models, knowing how they will help improve performance and outcomes.

Industry: I have a new, simple route to receive world-leading advice and support for market access, followed by a faster and more proportionate NICE assessment.



In addition, we will continue to deliver our core advice and guidance

DRAFT

In 2023/24 we anticipate delivering:

50

health technologies programme guidance

110

technology appraisals and highly specialised technologies guidance

17

New guidelines or updates to topic suites

11

quality standard updates

